Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses

Cell

Volumn 173, Issue 7, 2018, Pages 1783-1795.e14

  Sajadi, Mohammad Mohseni ^a,b   Dashti, Amir ^a   Rikhtegaran Tehrani, Zahra ^a,c   Tolbert, William D ^a   Seaman, Michael S ^d   Ouyang, Xin ^a   Gohain, Neelakshi ^a   Pazgier, Marzena ^a   Kim, Dongkyoon ^e   Cavet, Guy ^e   Yared, Jean ^a   Redfield, Robert R ^a   Lewis, George K ^a   DeVico, Anthony L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Atreca Inc   (United States)

Author keywords

antibody; broadly neutralizing antibody; HIV 1; humoral immunity; pan neutralization; repertoire

Indexed keywords

GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PROTEIN BINDING; RECOMBINANT PROTEIN; VIRUS RNA;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING SITE; BONE MARROW CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; NONHUMAN; PROTEIN DENATURATION; PROTEIN DOMAIN; PROTEOMICS; X RAY CRYSTALLOGRAPHY; AMINO ACID SEQUENCE; BIOSYNTHESIS; BLOOD; CHEMISTRY; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR DYNAMICS; PROTEIN TERTIARY STRUCTURE;

AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; BINDING SITES; CD4 ANTIGENS; CRYSTALLOGRAPHY, X-RAY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; RNA, VIRAL;

EID: 85046157216     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2018.03.061     Document Type: Article

References (58)

1. Boutz, D.R., Horton, A.P., Wine, Y., Lavinder, J.J., Georgiou, G., Marcotte, E.M., Proteomic identification of monoclonal antibodies from serum. Anal. Chem. 86 (2014), 4758–4766.
2. Briney, B.S., Willis, J.R., Finn, J.A., McKinney, B.A., Crowe, J.E. Jr., Tissue-specific expressed antibody variable gene repertoires. PLoS ONE, 9, 2014, e100839.
3. Brünger, A.T., Free R value: cross-validation in crystallography. Methods Enzymol. 277 (1997), 366–396.
4. de Taeye, S.W., Ozorowski, G., Torrents de la Peña, A., Guttman, M., Julien, J.P., van den Kerkhof, T.L., Burger, J.A., Pritchard, L.K., Pugach, P., Yasmeen, A., et al. Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell 163 (2015), 1702–1715.
5. Dey, B., Berger, E.A., Blocking HIV-1 gp120 at the Phe43 cavity: if the extension fits…. Structure 21 (2013), 871–872.
6. Dhillon, A.K., Donners, H., Pantophlet, R., Johnson, W.E., Decker, J.M., Shaw, G.M., Lee, F.H., Richman, D.D., Doms, R.W., Vanham, G., Burton, D.R., Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 81 (2007), 6548–6562.
7. Diskin, R., Scheid, J.F., Marcovecchio, P.M., West, A.P. Jr., Klein, F., Gao, H., Gnanapragasam, P.N., Abadir, A., Seaman, M.S., Nussenzweig, M.C., Bjorkman, P.J., Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334 (2011), 1289–1293.
8. Doria-Rose, N.A., Schramm, C.A., Gorman, J., Moore, P.L., Bhiman, J.N., DeKosky, B.J., Ernandes, M.J., Georgiev, I.S., Kim, H.J., Pancera, M., et al., NISC Comparative Sequencing Program. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509 (2014), 55–62.
9. Dugast, A.S., Arnold, K., Lofano, G., Moore, S., Hoffner, M., Simek, M., Poignard, P., Seaman, M., Suscovich, T.J., Pereyra, F., et al. Virus-driven inflammation is associated with the development of bNAbs in spontaneous controllers of HIV. Clin. Infect. Dis. 64 (2017), 1098–1104.
10. Finzi, A., Xiang, S.H., Pacheco, B., Wang, L., Haight, J., Kassa, A., Danek, B., Pancera, M., Kwong, P.D., Sodroski, J., Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol. Cell 37 (2010), 656–667.
11. Fouts, T.R., Tuskan, R., Godfrey, K., Reitz, M., Hone, D., Lewis, G.K., DeVico, A.L., Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J. Virol. 74 (2000), 11427–11436.
12. Georgiev, I.S., Joyce, M.G., Yang, Y., Sastry, M., Zhang, B., Baxa, U., Chen, R.E., Druz, A., Lees, C.R., Narpala, S., et al. Single-chain soluble BG505.SOSIP gp140 trimers as structural and antigenic mimics of mature closed HIV-1 env. J. Virol. 89 (2015), 5318–5329.
13. Guan, Y., Sajadi, M.M., Kamin-Lewis, R., Fouts, T.R., Dimitrov, A., Zhang, Z., Redfield, R.R., DeVico, A.L., Gallo, R.C., Lewis, G.K., Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc. Natl. Acad. Sci. USA 106 (2009), 3952–3957.
14. Guan, Y., Pazgier, M., Sajadi, M.M., Kamin-Lewis, R., Al-Darmarki, S., Flinko, R., Lovo, E., Wu, X., Robinson, J.E., Seaman, M.S., et al. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc. Natl. Acad. Sci. USA 110 (2013), E69–E78.
15. Halliley, J.L., Tipton, C.M., Liesveld, J., Rosenberg, A.F., Darce, J., Gregoretti, I.V., Popova, L., Kaminiski, D., Fucile, C.F., Albizua, I., et al. Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow. Immunity 43 (2015), 132–145.
16. Haynes, B.F., Mascola, J.R., The quest for an antibody-based HIV vaccine. Immunol. Rev. 275 (2017), 5–10.
17. Huang, J., Kang, B.H., Pancera, M., Lee, J.H., Tong, T., Feng, Y., Imamichi, H., Georgiev, I.S., Chuang, G.Y., Druz, A., et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515 (2014), 138–142.
18. Huang, J., Kang, B.H., Ishida, E., Zhou, T., Griesman, T., Sheng, Z., Wu, F., Doria-Rose, N.A., Zhang, B., McKee, K., et al. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity 45 (2016), 1108–1121.
19. Jardine, J.G., Kulp, D.W., Havenar-Daughton, C., Sarkar, A., Briney, B., Sok, D., Sesterhenn, F., Ereño-Orbea, J., Kalyuzhniy, O., Deresa, I., et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351 (2016), 1458–1463.
20. Javaherian, K., Langlois, A.J., McDanal, C., Ross, K.L., Eckler, L.I., Jellis, C.L., Profy, A.T., Rusche, J.R., Bolognesi, D.P., Putney, S.D., et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA 86 (1989), 6768–6772.
21. Karplus, P.A., Diederichs, K., Linking crystallographic model and data quality. Science 336 (2012), 1030–1033.
22. Kimura, M., The Neutral Theory of Molecular Evolution. 1983, Cambridge University Press, Cambridge.
23. Kwong, P.D., Mascola, J.R., Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37 (2012), 412–425.
24. LaRosa, G.J., Davide, J.P., Weinhold, K., Waterbury, J.A., Profy, A.T., Lewis, J.A., Langlois, A.J., Dreesman, G.R., Boswell, R.N., Shadduck, P., et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 249 (1990), 932–935.
25. Lavinder, J.J., Wine, Y., Giesecke, C., Ippolito, G.C., Horton, A.P., Lungu, O.I., Hoi, K.H., DeKosky, B.J., Murrin, E.M., Wirth, M.M., et al. Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proc. Natl. Acad. Sci. USA 111 (2014), 2259–2264.
26. Li, Y., Migueles, S.A., Welcher, B., Svehla, K., Phogat, A., Louder, M.K., Wu, X., Shaw, G.M., Connors, M., Wyatt, R.T., Mascola, J.R., Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13 (2007), 1032–1034.
27. Li, Y., Svehla, K., Louder, M.K., Wycuff, D., Phogat, S., Tang, M., Migueles, S.A., Wu, X., Phogat, A., Shaw, G.M., et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83 (2009), 1045–1059.
28. Lynch, R.M., Wong, P., Tran, L., O'Dell, S., Nason, M.C., Li, Y., Wu, X., Mascola, J.R., HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J. Virol. 89 (2015), 4201–4213.
29. Montezuma-Rusca, J.M., Moir, S., Kardava, L., Buckner, C.M., Louie, A., Kim, L.J., Santich, B.H., Wang, W., Fankuchen, O.R., Diaz, G., et al. Bone marrow plasma cells are a primary source of serum HIV-1-specific antibodies in chronically infected individuals. J. Immunol. 194 (2015), 2561–2568.
30. Popov, A.N., Bourenkov, G.P., Choice of data-collection parameters based on statistic modelling. Acta Crystallogr. D Biol. Crystallogr. 59 (2003), 1145–1153.
31. Ranasinghe, S., Soghoian, D.Z., Lindqvist, M., Ghebremichael, M., Donaghey, F., Carrington, M., Seaman, M.S., Kaufmann, D.E., Walker, B.D., Porichis, F., HIV-1 antibody neutralization breadth is associated with enhanced HIV-specific CD4+ T cell responses. J. Virol. 90 (2015), 2208–2220.
32. Robinson, J.E., Hastie, K.M., Cross, R.W., Yenni, R.E., Elliott, D.H., Rouelle, J.A., Kannadka, C.B., Smira, A.A., Garry, C.E., Bradley, B.T., et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun., 7, 2016, 11544.
33. Rusert, P., Kouyos, R.D., Kadelka, C., Ebner, H., Schanz, M., Huber, M., Braun, D.L., Hozé N., Scherrer, A., Magnus, C., et al., Swiss HIV Cohort Study. Determinants of HIV-1 broadly neutralizing antibody induction. Nat. Med. 22 (2016), 1260–1267.
34. Sajadi, M.M., Heredia, A., Le, N., Constantine, N.T., Redfield, R.R., HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS 21 (2007), 517–519.
35. Sajadi, M.M., Constantine, N.T., Mann, D.L., Charurat, M., Dadzan, E., Kadlecik, P., Redfield, R.R., Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J. Acquir. Immune Defic. Syndr. 50 (2009), 403–408.
36. Sajadi, M.M., Guan, Y., DeVico, A.L., Seaman, M.S., Hossain, M., Lewis, G.K., Redfield, R.R., Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J. Acquir. Immune Defic. Syndr. 57 (2011), 9–15.
37. Sajadi, M.M., Lewis, G.K., Seaman, M.S., Guan, Y., Redfield, R.R., DeVico, A.L., Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma. J. Virol. 86 (2012), 5014–5025.
38. Sajadi, M.M., Farshidpour, M., Brown, E.P., Ouyang, X., Seaman, M.S., Pazgier, M., Ackerman, M.E., Robinson, H., Tomaras, G., Parsons, M.S., et al. λ light chain bias associated with enhanced binding and function of anti-HIV env glycoprotein antibodies. J. Infect. Dis. 213 (2016), 156–164.
39. Sanders, R.W., Derking, R., Cupo, A., Julien, J.P., Yasmeen, A., de Val, N., Kim, H.J., Blattner, C., de la Peña, A.T., Korzun, J., et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog., 9, 2013, e1003618.
40. Sather, D.N., Stamatatos, L., Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine 28:Suppl 2 (2010), B8–B12.
41. Scheid, J.F., Mouquet, H., Feldhahn, N., Seaman, M.S., Velinzon, K., Pietzsch, J., Ott, R.G., Anthony, R.M., Zebroski, H., Hurley, A., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458 (2009), 636–640.
42. Seaman, M.S., Janes, H., Hawkins, N., Grandpre, L.E., Devoy, C., Giri, A., Coffey, R.T., Harris, L., Wood, B., Daniels, M.G., et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84 (2010), 1439–1452.
43. Simek, M.D., Rida, W., Priddy, F.H., Pung, P., Carrow, E., Laufer, D.S., Lehrman, J.K., Boaz, M., Tarragona-Fiol, T., Miiro, G., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83 (2009), 7337–7348.
44. Simonsen, M.M.T., Pedersen, C.N.S., Rapid neighbor-joining. Crandall, K.A., Lagergren, J.L., (eds.) WABI 2008, 2008, Springer, Heidelberg, 113–122.
45. Tan, Y.C., Blum, L.K., Kongpachith, S., Ju, C.H., Cai, X., Lindstrom, T.M., Sokolove, J., Robinson, W.H., High-throughput sequencing of natively paired antibody chains provides evidence for original antigenic sin shaping the antibody response to influenza vaccination. Clin. Immunol. 151 (2014), 55–65.
46. Trkola, A., Pomales, A.B., Yuan, H., Korber, B., Maddon, P.J., Allaway, G.P., Katinger, H., Barbas, C.F. 3rd, Burton, D.R., Ho, D.D., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69 (1995), 6609–6617.
47. Vogel, T., Kurth, R., Norley, S., The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. J. Immunol. 153 (1994), 1895–1904.
48. Volpe, J.M., Cowell, L.G., Kepler, T.B., SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinations. Bioinformatics 22 (2006), 438–444.
49. Walker, L.M., Phogat, S.K., Chan-Hui, P.Y., Wagner, D., Phung, P., Goss, J.L., Wrin, T., Simek, M.D., Fling, S., Mitcham, J.L., et al., Protocol G Principal Investigators. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326 (2009), 285–289.
50. Walker, L.M., Simek, M.D., Priddy, F., Gach, J.S., Wagner, D., Zwick, M.B., Phogat, S.K., Poignard, P., Burton, D.R., A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog., 6, 2010, e1001028.
51. Weiss, M.S., Global indicators of X-ray data quality. Acta Crystallogr. Sect. A Found. Crystallogr. 34 (2001), 130–135.
52. West, A.P. Jr., Diskin, R., Nussenzweig, M.C., Bjorkman, P.J., Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA 109 (2012), E2083–E2090.
53. Williams, L.D., Ofek, G., Schatzle, S., McDaniel, J.R., Lu, X., Nicely, N.I., Wu, L., Lougheed, C.S., Bradley, T., Louder, M.K., et al. Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Sci. Immunol., 2, 2017, eaal2200.
54. Wine, Y., Boutz, D.R., Lavinder, J.J., Miklos, A.E., Hughes, R.A., Hoi, K.H., Jung, S.T., Horton, A.P., Murrin, E.M., Ellington, A.D., et al. Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response. Proc. Natl. Acad. Sci. USA 110 (2013), 2993–2998.
55. Wine, Y., Horton, A.P., Ippolito, G.C., Georgiou, G., Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire. Curr. Opin. Immunol. 35 (2015), 89–97.
56. Wu, L., Gerard, N.P., Wyatt, R., Choe, H., Parolin, C., Ruffing, N., Borsetti, A., Cardoso, A.A., Desjardin, E., Newman, W., et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384 (1996), 179–183.
57. Wu, X., Yang, Z.Y., Li, Y., Hogerkorp, C.M., Schief, W.R., Seaman, M.S., Zhou, T., Schmidt, S.D., Wu, L., Xu, L., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329 (2010), 856–861.
58. Zhou, T., Georgiev, I., Wu, X., Yang, Z.Y., Dai, K., Finzi, A., Kwon, Y.D., Scheid, J.F., Shi, W., Xu, L., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329 (2010), 811–817.